13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02200718 (ClinicalTrials.gov) | December 31, 2020 | 17/7/2014 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | NULL | Not yet recruiting | 5 Years | 17 Years | All | 12 | Phase 1 | United States |
| 2 | NCT02149706 (ClinicalTrials.gov) | March 9, 2020 | 24/5/2014 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | cro | Not yet recruiting | 18 Years | 70 Years | All | 150 | Phase 2 | United States |
| 3 | NCT02057159 (ClinicalTrials.gov) | March 9, 2020 | 4/2/2014 | A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | Secondary Progress Multiple Sclerosis;Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Placebo | Immune Response BioPharma, Inc. | cro | Recruiting | 18 Years | 50 Years | All | 200 | Phase 2/Phase 3 | United States |
| 4 | EUCTR2006-003384-30-SK (EUCTR) | 26/02/2007 | 08/11/2006 | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | Multiple Sclerosis | Product Name: NeuroVax 300ug/mL Dose for IM Injection Product Code: IR902 Other descriptive name: VB6S5 Other descriptive name: VB13S1 Other descriptive name: VB5S2 | The Immune Response Corporation | NULL | Not Recruiting | Female: yes Male: yes | 200 | Phase 2 | Slovakia |